Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
NCT04698850Phase 4Withdrawn
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brolucizumab in retinal angiomatous proliferation (RAP), sponsored by Faculty Hospital Kralovske Vinohrady. Planned start Jan 2021; status: withdrawn.
02
Drugs
brolucizumab
03
Conditions
retinal angiomatous proliferation (RAP)
Beyond the preview
Go deeper on NCT04698850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04698850.